Singapore Pharmaceutical Market is driven by Public Private Partnerships in R&D and Expansion of Multinational Companies in Local Market: Ken Research

World Class manufacturing facilities, skilled workforce, expansion of product portfolio by major pharmaceutical companies, government grants and tax incentives were the key factors driving growth in Singapore pharmaceutical Market. Singapore Pharmaceutical Market can be characterized by the presence of best-in-class infrastructure, integrated and advanced hubs for pharmaceutical manufacturing and research and access to regional markets…

Singapore Pharmaceutical Market is expected to Reach USD 1.8 Billion by 2022: Ken Research

Singapore Pharmaceutical Market engages over 50 top global biomedical science firms and 30 public research institutes which aim to create a biomedical ecosystem that concentrates infrastructure and technology Singapore has developed 2 biomedical hubs namely Biopolis and Tuas Biomedical Park which facilitate the cooperation between public sector research centers with private labs and pharmaceutical manufacturing…

Singapore Pharmaceutical Market Outlook to 2022: Ken Research

The report titled “Singapore Pharmaceutical Market Outlook to 2022 – by Prescription & OTC Drugs and by Patented & Generic Drugs” covers aspects such as pharmaceutical market segment (by Prescription & OTC Drugs, by Patented & Generic Drugs), competitive landscape of major players in the Singapore pharmaceutical market including Haw Par Corporation, Beacon Pharmaceuticals, GSK,…